GEHC:NASDAQ

GE HealthCare Technologies (GEHC) is trading at $75.63, approximately 23% above the DCF‑derived fair value of $56.28. The stock’s forward P/E of 13.6 is well below the medical‑devices industry average of 25.4, suggesting a relative value advantage. Revenue grew 7.1% year‑over‑year to $20.6 bn and operating margins sit at 15.8%, underscoring solid profitability. Cash on hand exceeds $4.5 bn, while the payout ratio is a modest 3%, indicating a sustainable dividend. Technicals are mixed – the price sits beneath the 20‑day (80.64) and 50‑day (81.78) SMAs, the MACD is bearish, and RSI is at 35.8, hinting at short‑term weakness. Nonetheless, the stock remains above its 200‑day SMA (76.86) and near a key support level of $72.30, limiting downside risk.
Recent Q4 results beat consensus, driven by strong growth in the Pharmaceutical Diagnostics segment and a record backlog, which analysts have highlighted as a catalyst. Barclays upgraded its price target to $87, and the consensus analyst recommendation is a “Buy” with a median target of $95, reflecting upside potential. The company’s diversified portfolio across imaging, advanced visualization, patient‑care solutions, and diagnostics provides a resilient revenue base amid modest regulatory headwinds. While beta of 1.33 and 30‑day volatility of 30% signal higher market sensitivity, the sector’s defensive nature and low currency exposure temper overall risk. Given the blend of value pricing, growth momentum, and sustainable dividend, the medium‑ to long‑term outlook is positive. Investors should watch the near‑term price action around the $72–$78 range for entry, while the longer horizon remains aligned with the analyst‑driven upside to the mid‑$90s.